Endpoints 11: Kali Therapeutics almost bought drugs from China. Instead, its in-house pipeline is thriving

Endpoints 11 winner: Weihao Xu built Kali Therapeutics with $18M, no lab and Chinese vendors — then sold its lead T cell engager to Sanofi for $180M upfront. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…

Source: Endpoints News